Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test (ADAPT-PSA)
Prostate Cancer, Prostate Inflammation, PSA
About this trial
This is an interventional treatment trial for Prostate Cancer focused on measuring Prostate-specific antigen, PSA test, Prostate biopsy, non-steroidal anti-inflammatory drugs NSAIDS
Eligibility Criteria
Inclusion Criteria: All men with an elevated PSA level (as designated by their medical provider) will be invited to participate in the study Exclusion Criteria: Inability to use NSAIDs (allergy, side effects) History of peptic ulcer disease or GI bleeding Any bleeding disorders Chronic kidney disease: eGlomerular Filtration Rate < 45 Heart failure, significant heart disease Poorly controlled hypertension Signs or symptoms of urinary tract infections Use of 5-alpha reductase inhibitors (finasteride, dutasteride) within past 6 months History of prostate cancer Urinary tract instrumentation in the past 2 months (catheter, endoscopy) Regular NSAIDs use (> once per week) Daily Aspirin use (325 mg or 81 mg), UNLESS it can be held for the study period Other anti-platelet or anticoagulant therapy Steroids use (except occasionally inhaled formulations) Liver disease, abnormal liver function tests
Sites / Locations
- Albany Medical CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Repeat serum PSA test
Treatment with NSAIDS
Repeat PSA test at 6 (± 1) weeks, without any treatment
Treatment with NSAIDS (Ibuprofen 400 mg, 3 times per day or Naproxen 220 mg, twice per day for 10 days), then repeat PSA test at 6 (± 1) weeks